All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

In solid tumors, complex and reciprocal interactions between neoplastic cells and surrounding cells lead to a tumor tissue compartment often referred to as reactive stroma, desmoplastic stroma or tumor microenvironment. A dominant component of the tumor stroma are fibroblasts, which are known to play determinant roles in tumor initiation, expansion, dissemination and metastasis \[[@pone.0192157.ref001]\]. Cancer-associated fibroblasts (CAFs) is a generic name given to a heterogeneous group of non-epithelial, non-immune cells with a likely mesenchymal lineage, located within tumors or at the tumor borders \[[@pone.0192157.ref002]\]. Quiescent connective tissue fibroblasts are generally considered indolent, exhibiting rather low metabolic and transcriptomic activity, and expressing classical mesenchymal markers such as vimentin, integrin α1β1 or FSP-1 \[[@pone.0192157.ref003]\]. Fibroblasts associated with tumors normally display an activated phenotype, and depending on their origin, morphology or spatial distribution, they may receive different names such as myofibroblasts, activated tumor fibroblasts, activated stellate cells, bone marrow-derived mesenchymal stromal cells or pericytes \[[@pone.0192157.ref004], [@pone.0192157.ref005]\]. Several markers such as αSMA, FAP-1, desmin, podoplanin, neuron-glial antigen 2 (NG2) and PDGF receptors-α and -β are used to identify CAFs. However, due to the great plasticity of this cell population, none of these markers can be used as a universal marker for all CAFs as their expression is likely to be temporal and context dependent \[[@pone.0192157.ref006]\]. Different CAF subsets, expressing overlapping and non-overlapping markers, can be identified in a single tumor. However, it remains unknown whether the various CAF subtypes in tumors have different functions. In non-small cell lung cancer (NSCLC), several studies have explored the prognostic significance of established CAF markers such as podoplanin, vimentin, FAP-1, αSMA or PDGFRβ. In most cases, these markers have demonstrated unfavorable outcomes related to survival ([Table 1](#pone.0192157.t001){ref-type="table"}).

10.1371/journal.pone.0192157.t001

###### Prognostic role of different CAF markers in lung cancer cohorts.

![](pone.0192157.t001){#pone.0192157.t001g}

  Fibroblast marker         Tumor subtype        Samples (n)          Technique              Prognostic impact                      Ref.
  ------------------------- -------------------- -------------------- ---------------------- -------------------------------------- -------------------------------------
  **αSMA**                  NSCLC Stage I-III    78                   IHC whole tissue/PCR   Unfavorable                            Chen \[[@pone.0192157.ref007]\]
  NSCLC Stage I-IIIA        536                  IHC/TMA              No significance        Kilvaer \[[@pone.0192157.ref008]\]     
  **αSMA/ Vimentin**        ADC                  102                  IHC whole tissue       Unfavorable                            Shu \[[@pone.0192157.ref009]\]
  **Vimentin**              NSCLC Stage I-IIIA   335                  IHC/TMA                No significance                        Al-Saad \[[@pone.0192157.ref010]\]
  **Podoplanin**            ADC Stage-I          304                  IHC whole tissue       Unfavorable                            Ito \[[@pone.0192157.ref011]\]
  ADC                       177                  IHC whole tissue     Unfavorable            Kawase \[[@pone.0192157.ref012]\]      
  ADC (post chemotherapy)   87                   IHC whole tissue     Unfavorable            Koriyama \[[@pone.0192157.ref013]\]    
  ADC N2 Stage-III          112                  IHC Lymph nodes      Unfavorable            Neri \[[@pone.0192157.ref014]\]        
  SCLC                      36                   IHC whole tissue     Favorable              Takahashi \[[@pone.0192157.ref015]\]   
  NSCLC                     400                  IHC/TMA              Unfavorable            Kitano \[[@pone.0192157.ref016]\]      
  SCC Stage-I               142                  IHC whole tissue     Unfavorable            Ono \[[@pone.0192157.ref017]\]         
  **FAP-1**                 NSCLC                59                   IHC whole tissue       Unfavorable                            Liao \[[@pone.0192157.ref018]\]
  NSCLC Stage I-III         536                  IHC/TMA              Favorable in SCC       Kilvaer \[[@pone.0192157.ref008]\]     
  **MMP-2**                 NSCLC Stage I-IIIA   218                  IHC whole tissue       Unfavorable                            Ishikawa \[[@pone.0192157.ref019]\]
  NSCLC                     212                  IHC whole tissue     Unfavorable            Leinonen \[[@pone.0192157.ref020]\]    
  **CD99**                  NSCLC                190/240 (2cohorts)   IHC/TMA                Favorable                              Edlund \[[@pone.0192157.ref021]\]
  **PDGFRβ**                NSCLC                190                  IHC/TMA                No significance                        Edlund \[[@pone.0192157.ref021]\]

Abbreviations: NSCLC, non-small cell lung cancer; IHC, immunohistochemistry; PCR, polymerase chain reaction; ADC, adenocarcinoma; SCLC, small-cell lung cancer; SCC, squamous cell carcioma

Despite the widely acknowledged role of CAFs in malignant progression, the understanding of their relationship with tumor-infiltrating lymphocytes (TILs) is incomplete. Emerging evidence propose that the tumor stroma influence tumor immunity and response to immunotherapy \[[@pone.0192157.ref022]\]. CAFs are suggested to interfere with tumor immunity in multiple ways, including remodeling of extracellular matrix, shaping the phenotype of vessels and endothelial cells and directly influencing the migration and function of inflammatory and immune cells by the release of paracrine signals. In general, CAFs are believed to exert pro-inflammatory and immunosuppressive functions in tumors \[[@pone.0192157.ref023], [@pone.0192157.ref024]\]. However, some studies have challenged this view, arguing that different CAF subsets may exert opposite functions, and that in a context-dependent manner, CAFs may aid the antitumor immune responses \[[@pone.0192157.ref025]\]. In the context of cancer immunotherapy, selective depletion of CAF^FAP^ has been shown to synergize with immune-checkpoint inhibitors in pre-clinical models \[[@pone.0192157.ref026]\], thus proposing that targeting immunosuppressive elements of the tumor stroma may aid to the efficacy of immuno-therapeutic interventions.

We have previously explored the prognostic significance of CAF-markers in the stroma of resected NSCLC tumors \[[@pone.0192157.ref008]\], with the intriguing finding that high CAF^FAP^ levels were associated with an improved prognosis in patients with squamous cell carcinoma. Earlier studies on NSCLC have also highlighted the prognostic relevance of other stromal markers such as CD99 \[[@pone.0192157.ref021]\], Forkhead Box F1 \[[@pone.0192157.ref027]\], and Cox-2 \[[@pone.0192157.ref028]\]. In the present study, we explore associations between CAFs and immune cell infiltrates in NSCLC tumor tissues. Additionally, we investigate whether CAFs impact patient survival according to different levels of immune cell infiltration.

Materials and methods {#sec006}
=====================

Patients and clinical samples {#sec007}
-----------------------------

This study presents data on a cohort of 536 unselected stage IA-IIIA NSCLC patients. A detailed description of the cohort was published previously by our group \[[@pone.0192157.ref029]\]. Briefly, the included patients were staged after the 7^th^ edition of the UICC TNM classification \[[@pone.0192157.ref030]\], and histologically classified according to the 2013 edition of the pathological classification of lung cancer \[[@pone.0192157.ref031]\]. Of the 536 patients, 289 were squamous cell carcinomas, 201 were adenocarcinomas and 46 were classified as NOS. Most patients classified as NOS were previously considered as large cell carcinoma, while a few patients were too undifferentiated to be classified. The Regional Committee for Medical and Health Research Ethics (REK-Nord) approved the use of human material for this study (Project-ID: 2016/2307/REK-Nord). Due to the retrospective nature of the study, and the fact that two thirds of the study population was deceased at time of study initiation, the need of written informed consent was waivered. All methods involving human material were performed in accordance with relevant guidelines and regulations.

Tissue micro-array construction, immunohistochemistry and scoring {#sec008}
-----------------------------------------------------------------

The work-flow for sample preparation, tissue micro-array (TMA) construction, immunohistochemistry (IHC) and scoring of TMA-slides is extensively documented \[[@pone.0192157.ref008], [@pone.0192157.ref029], [@pone.0192157.ref032]\]. In brief, representative areas of primary lung tumor stroma specimens were identified on H&E slides. Two duplicate tissue cores were collected from the primary tumor blocks based on the overlay of the H&E stained slides. TMAs were assembled using a Beecher Instruments tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, USA). Blocks were sectioned with 4 μm thickness and heated over-night at 60°C. The IHC staining procedures- including validations of antibodies---for FAP-1 and αSMA \[[@pone.0192157.ref008]\], CD3 (pan T-cell marker), CD4 (T-helper cells), CD8 (cytotoxic T-cells), CD20 (B-cells) and CD45RO (T-memory cells) and CD1A (Dendritic cells), CD56 (Natural Killer cells) and CD68 (macrophages) \[[@pone.0192157.ref033]\] were previously reported. The [S1 Table](#pone.0192157.s004){ref-type="supplementary-material"} includes a summary of staining procedures for the CAF markers \[[@pone.0192157.ref029]\]. Expert pathologists established semi-quantitative cut-offs for each marker. Immune- and CAF markers were scored as percentages of positive cells from the total number of cells in the stromal area, using the following thresholds: CD3, CD4, CD8, CD20 and CD45RO 0, = \<1%, 1 = 1--5%, 2 = 6--25%, 3 = 26--50%, 4 = \>50% (29); CD1A and CD56, 0 = \< 1%, 1 = \> 1%; CD68, 0 = \<25%, 1 = \> 25% \[[@pone.0192157.ref033]\]; FAP1, \[SMA, PDGFRα and PDGFRβ 0 = \<1%, 1 = 1--10%, 2 = 11--50%,d 3 = \> 50% \[[@pone.0192157.ref008]\]. Vimentin was scored based on intensity and density with the following thresholds: intensity 1 = weak, 2 = intermediate and 3 = strong \[[@pone.0192157.ref010]\]. Micro vessels density and lymphatic micro vessel density was scored based on the total number of vessels found per core, using the following thresholds: CD34, 0 = negative; 1 = (1--10 vessels per core); 2 = (11--20 vessels per core); 3 = (\>20 vessels per core) \[[@pone.0192157.ref030]\]; D240, 0 = negative; 1 = (one vessel per core); 2 = (2--5 vessels per core); 3 = (\>5 vessels per core) \[[@pone.0192157.ref034]\]. All TMA cores were scored independently by two investigators, blinded to each other and to patient data. High expression of CAF-markers were defined as: \> 0.5 (FAP-1), \>2 (αSMA), \>1,75 (PDGFRα) and \> 1.5 (PDGFRβ) utilizing an optimal cut-off approach ([Fig 1](#pone.0192157.g001){ref-type="fig"}). The cut-offs used for FAP1 and αSMA were previously defined \[[@pone.0192157.ref008]\]. In order to evenly distribute CAF high and low patients in subgroup analyses based on immune cell infiltration, high expression of immune markers (CD3 and CD8) was decided bases on a median cut-off approach ([S1 Fig](#pone.0192157.s001){ref-type="supplementary-material"})

![Immunostaining of TMA cores showing low vs high score of the four main CAFs markers.\
(**A)** PDGFRβ; (**B)** PDGFRα; (**C)** FAP-1; (**D)** αSMA. Abbreviations: PDGFR, platelet-derived growth factor receptor; FAP-1, Fibroblast activating protein 1; αSMA, alpha-smooth muscle actin.](pone.0192157.g001){#pone.0192157.g001}

Statistical methods {#sec009}
-------------------

All statistical analyses were conducted in RStudio, version 1.0.136 with R version 3.3.2 and packages \"sjmisc\", \"Hmisc\", \"survival\", \"ggplot2\", \"reshape2\", \"grid\", \"gridExtra\" and \"cowplot\". Associations between the dichotomized markers and clinicopathological variables were tested with Chi-square or Fisher\'s exact tests. Due to the semi-quantitative scoring of the investigated markers, Spearman\`s rank-correlation was used to examine the between-marker correlations and visualized utilizing heat-maps and hierarchical clustering. Survival analyses were conducted and visualized using the log-rank test and the Kaplan-Meier method To allow the investigation of markers in the presence of other co-variables from the same dataset, Cox proportional hazards models were fitted to the data. A supervised iterative process, based on significance levels in each step, was used to select the variables included in the final models. The significance level used for all statistical tests was P \< 0.05.

Results {#sec010}
=======

Associations between markers and clinicopathological variables {#sec011}
--------------------------------------------------------------

No significant associations were observed between neither PDGFRα, nor vimentin expression and clinicopathological variables ([Table 2](#pone.0192157.t002){ref-type="table"}). Low expression of PDGFRβ was associated with normal ECOG status (P = 0.003) and high expression of αSMA was associated with vascular invasion (P = 0.012). No associations between FAP-1 and clinicopathological variables was observed, as previously reported by our group \[[@pone.0192157.ref008]\].

10.1371/journal.pone.0192157.t002

###### Correlations between marker expressions and clinicopathological variables with stromal PDGFRα, PDGFRβ, αSMA and vimentin (chi-square and Fisher\'s exact tests).

![](pone.0192157.t002){#pone.0192157.t002g}

                          PDGFRα S   PDGFRβ S   αSMA    Vimentin                                                
  ----------------------- ---------- ---------- ------- ---------- ----- ------- ----- ----- ------- ----- ---- -------
  **Age**                                       0.431                    0.443               0.341              0.594
      \<65                146        68                 124        90            148   79            100   35   
      ≥65                 207        81                 176        109           214   94            133   55   
  **Gender**                                    0.225                    1.000               0.138              0.331
      Female              109        55                 97         64            123   47            51    25   
      Male                244        94                 203        135           239   126           182   65   
  **Weight-loss**                               0.659                    0.119               0.602              0.808
      \<10%               319        132                275        173           327   153           211   80   
      \>10%               34         17                 25         26            35    20            22    10   
  **Smoking status**                            0.842                    0.100               0.726              0.041
      Never               10         4                  12         2             10    7             13    0    
      Present             222        98                 184        132           233   109           146   63   
      Previous            121        47                 104        65            119   57            74    27   
  **ECOG**                                      0.756                    0.003               0.704              0.860
      Normal              203        91                 193        98            211   98            136   51   
      Slightly            125        48                 91         82            125   65            85    33   
      In bed\<50%         25         10                 16         19            26    10            12    6    
  **Histology**                                 0.069                    0.093               0.393              0.303
      SCC                 190        83                 152        120           198   90            137   53   
      ADC                 127        60                 124        64            137   64            77    25   
      NOS                 36         6                  24         15            27    19            19    12   
  **T-stage**                                   0.159                    0.840               0.505              0.888
      T1a                 49         22                 45         26            53    21            25    11   
      T1b                 68         20                 54         34            63    31            42    15   
      T2a                 127        49                 101        71            128   61            86    36   
      T2b                 42         29                 46         25            48    27            33    14   
      T3                  64         26                 51         40            68    29            47    14   
      T4                  3          3                  3          3             2     4             0     0    
  **N-stage**                                   0.273                    0.911               0.541              0.227
      N0                  237        105                202        136           248   116           159   64   
      N1                  85         27                 68         42            75    42            58    16   
      N2                  31         17                 30         21            39    15            16    10   
  **P-stage**                                   0.769                    0.938               0.875              0.954
      IA                  93         34                 79         47            94    40            53    21   
      IB                  79         33                 67         43            81    41            52    23   
      IIA                 82         32                 65         45            76    42            63    21   
      IIB                 48         23                 43         29            51    24            35    14   
      IIIA                51         27                 46         35            60    26            30    11   
  **Differentiation**                           0.129                    0.250               0.688              0.917
      Poor                153        59                 131        78            160   70            98    39   
      Moderate            152        77                 138        91            158   82            104   38   
      Well                48         13                 31         30            44    21            31    13   
  **Vascular invasion**                         0.520                    0.906               0.012              0.236
      No                  292        119                244        163           306   130           200   72   
      Yes                 60         29                 55         35            55    42            33    18   

Abbreviations: PDGFR, platelet derived growth factor; αSMA, alpha-smooth muscle actin; S, stroma; ECOG, Eastern cooperative oncology group; SCC, squamous cell carcinoma; ADC, adenocarcinoma; NOS, not otherwise specified

Correlations between CAF markers {#sec012}
--------------------------------

[Fig 2A](#pone.0192157.g002){ref-type="fig"} and [S2A and S2B Fig](#pone.0192157.s002){ref-type="supplementary-material"} summarizes the correlations between different CAF-markers investigated in the overall cohort and the two main histological subgroups of NSCLC, respectively. In the overall cohort, hierarchical clustering suggested a CAF phenotype in patients expressing vimentin, FAP-1 and PDGFRα and -β. On the other hand αSMA was only weakly associated with the other CAF-markers (-0.2\<R\<0.2). Considering correlations with R-values \< -0.2 and \> 0.2: **1)** PDGFRα was associated with FAP-1 (R = 0.28) and PDGFRβ (R = 0.33); **2)** PDGFRβ was associated with vimentin (R = 0.24) and FAP-1 (R = 0.32); and **3)** αSMA was associated with Masson\'s trichrome (MT) (R = 0.20). In addition, correlations of CAF-markers with angio- and lymphangigenic markers CD34 and D240 had low R-values (\< 0.2). Other significant, but weak (-0.2 \< R \< 0.2) associations were also observed. Correlations in histological subgroups were mostly similar to those observed in the overall cohort ([S2A and S2B Fig](#pone.0192157.s002){ref-type="supplementary-material"}). Distinct expression patterns of FAP-1 and αSMA (both considered hallmarks of activated CAFs) in the same tissue specimens are shown in [Fig 3](#pone.0192157.g003){ref-type="fig"}.

![**Spearman\'s rank correlations** between **A)** Different CAF markers and **B)** CAF markers and markers of leukocyte subsets. \*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001. Abbreviations: CAF, cancer-associated fibroblast; Vim, vimentin; FAP-1, Fibroblast activating protein 1; PDGFR, platelet-derived growth factor receptor; αSMA, alpha-smooth muscle actin; MT, Masson\'s trichrome; CD, cluster of differentiation.](pone.0192157.g002){#pone.0192157.g002}

![Double staining of FAP-1 & αSMA showing distinct expression patterns: in three randomly selected TMA cores corresponding to three NSCLC patients co-stained with FAP-1(purple) and αSMA(yellow).](pone.0192157.g003){#pone.0192157.g003}

Correlations between CAFs and immune-cell markers {#sec013}
-------------------------------------------------

[Fig 2B](#pone.0192157.g002){ref-type="fig"} and [S2C and S2D Fig](#pone.0192157.s002){ref-type="supplementary-material"} summarizes the correlations between CAF- and immune-cell markers in the overall cohort and the two main histological subtypes of NSCLC, respectively. No clear strong correlations between CAF- and immune-markers were observed. Considering correlations with R-values \<-0.2 and \> 0.2; **1)** FAP-1 was positively associated with FOXP3 (R = 0.231); **2)** PDGFRα was positively associated with CD3 (R = 0.236) and CD20 (R = 0.201) and **3)** PDGFRβ was positively associated with FOXP3 (R = 0.221). Other significant, but weak (R \< 0.2) associations between CAF- and immune-markers was observed. Correlations in histological subgroups were mostly similar and similar to those of the overall cohort ([S2C and S2D Fig](#pone.0192157.s002){ref-type="supplementary-material"}). Images of TMA cores representing tumors with different scores of CD3+ and CD8+ cells are shown in [S1 Fig](#pone.0192157.s001){ref-type="supplementary-material"}.

Survival analyses {#sec014}
-----------------

[Fig 4](#pone.0192157.g004){ref-type="fig"} and [S3 Fig](#pone.0192157.s003){ref-type="supplementary-material"} shows the survival curves of PDGFRα, PDGFRβ, FAP-1 and αSMA in patients expressing high and low levels of CD8 and CD3 respectively. In univariate analyses, high expression of FAP-1 was a significant positive marker for survival in patients with high expression of CD8 (*P* = 0.013) and CD3 (P = 0.042), while high expression of PDGFRβ was a significant negative marker for survival in patients with low expression of CD8 (*P* = 0.005) and near significant in patients with low expression of CD3 (*P* = 0.052).

![**Disease-specific survival curves** for: PDGFRα in patients expressing high levels of **A)** CD8 and **B)** CD3, PDGFRβ in patients expressing high levels of **C)** CD8 and **D)** CD3, FAP-1 in patients expressing high levels of **E)** CD8 and **F)** CD3 and αSMA in patients expressing high levels of **G)** CD8 and **H)** CD3. Abbreviations: FAP-1, Fibroblast activating protein 1; PDGFR, platelet-derived growth factor receptor; αSMA, alpha-smooth muscle actin.](pone.0192157.g004){#pone.0192157.g004}

In multivariable analyses, summarized in [Table 3](#pone.0192157.t003){ref-type="table"}, FAP-1 was an independent positive marker for survival in patients with high, but not low, expression of CD8 (HR 0.42, 95% CI 0.24--0.74, *P* = 0.003, [Table 3A](#pone.0192157.t003){ref-type="table"}) and PDGFRβ was an independent negative marker of survival in patients with low, but not high, expression of CD8 (HR 1.85, 95% CI 1.28--2.66, *P* \< 0.001, [Table 3E](#pone.0192157.t003){ref-type="table"}). Neither FAP-1, nor PDGFRβ were independent markers for survival in patients with high or low expression of CD3 ([Table 3C, 3D, 3G and 3H](#pone.0192157.t003){ref-type="table"}).

10.1371/journal.pone.0192157.t003

###### Multivariable models of FAP1 (A-D) and PDGFRβ (E-H) predicting survival of NSCLC patients with high and low expression of CD8 (A, C, E and G) and CD3 (B D, F and H, Cox regression analysis).

![](pone.0192157.t003){#pone.0192157.t003g}

  ----------------------- ------------------- ------------------ ------------------- ----------------- ------------------- --------- ------------------- ---------
                          **(A) CD8 High**    **(B) CD3 High**   **(C) CD8 Low**     **(D) CD3 Low**                                                     

                          **HR**\             ***P***            **HR**\             ***P***           **HR**\             ***P***   **HR**\             ***P***
                          **(95% CI)**                           **(95% CI)**                          **(95% CI)**                  **(95% CI)**        

  **FAP1**                                                                                                                                               

  Low                     1                                      1                                     1                             1                   

  High                    0.42(0.24--0.74)    0.003              0.75(0.45--1.25)    0.266             0.99(0.65--1.49)    0.954     0.84(0.54--1.31)    0.452

  **Gender**                                                                                                                                             

  Female                  1                                      1                                     1                             1                   

  Male                    2.3(1.37--3.85)     0.002              1.84(1.18--2.84)    0.007             1.48(0.98--2.23)    0.063     1.3(0.79--2.12)     0.302

  **Histology**                                                                                                                                          

  SCC                     1                                      1                                     1                             1                   

  ADC                     3.13(1.91--5.16)    \<0.001            2.25(1.45--3.48)    \<0.001           1.16(0.78--1.73)    0.451     1.11(0.72--1.71)    0.647

  NOS                     1.92(0.76--4.88)    0.170              2.24(1.12--4.48)    0.022             0.96(0.51--1.8)     0.894     0.56(0.24--1.27)    0.166

  **ECOG**                                                                                                                                               

  Normal                  1                                      1                                     1                             1                   

  Slightly reduced        1.98(1.21--3.23)    0.006              1.36(0.89--2.08)    0.157             1.29(0.9--1.87)     0.171     1.53(1.02--2.29)    0.040

  In bed \<50%            2.92(1.11--7.65)    0.029              1.86(0.83--4.2)     0.133             1.36(0.62--2.99)    0.447     1.08(0.41--2.82)    0.880

  **P-stage**                                                                                                                                            

  IA                      1                                      1                                     1                             1                   

  IB                      1.25(0.55--2.83)    0.596              1.39(0.7--2.74)     0.345             1.16(0.64--2.11)    0.616     1.08(0.54--2.15)    0.836

  IIA                     2.16(1.05--4.45)    0.036              1.95(1.03--3.7)     0.041             1.37(0.74--2.57)    0.320     1.69(0.86--3.33)    0.130

  IIB                     1.6(0.58--4.4)      0.361              1.48(0.64--3.41)    0.354             2.93(1.69--5.09)    \<0.001   4.17(2.29--7.59)    \<0.001

  IIIA                    5.3(2.49--11.28)    \<0.001            4.36(2.28--8.3)     \<0.001           4.2(2.34--7.53)     \<0.001   6.68(3.43--12.98)   \<0.001

  **Vascular invasion**                                                                                                                                  

  No                      1                                      1                                     1                             1                   

  Yes                     2.84(1.61--5)       \<0.001            2.14(1.34--3.44)    0.002             1.57(1.03--2.41)    0.037     1.67(1--2.78)       0.048

                          **(E) CD8 High**    **(F) CD3 High**   **(G) CD8 Low**     **(H) CD3 Low**                                                     

                          **HR**\             ***P***            **HR**\             ***P***           **HR**\             ***P***   **HR**\             ***P***
                          **(95% CI)**                           **(95% CI)**                          **(95% CI)**                  **(95% CI)**        

  **PDGFRβ**                                                                                                                                             

  Low                     1                                      1                                     1                             1                   

  High                    0.89(0.55--1.44)    0.626              1.17(0.77--1.79)    0.464             1.85(1.28--2.66)    \<0.001   1.45(0.97--2.17)    0.071

  **Gender**                                                                                                                                             

  Female                  1                                      1                                                                                       

  Male                    2.19(1.29--3.74)    0.004              1.8(1.15--2.8)      0.010                                                               

  **Histology**                                                                                                                                          

  SCC                     1                                      1                                                                                       

  ADC                     2.84(1.73--4.67)    \<0.001            2.22(1.42--3.46)    \<0.001                                                             

  NOS                     1.36(0.5--3.68)     0.546              1.93(0.95--3.93)    0.069                                                               

  **ECOG**                                                                                                                                               

  Normal                  1                                      1                                                                                       

  Slightly reduced        1.88 (1.12--3.15)   0.017              1.29(0.83--2.02)    0.254                                                               

  In bed \<50%            2.51 (0.97--6.52)   0.059              1.76(0.77--4)       0.179                                                               

  **P-stage**                                                                                                                                            

  IA                      1                                      1                                     1                             1                   

  IB                      1.33 (0.59--3.04)   0.493              1.45 (0.73--2.89)   0.292             1.17 (0.64--2.14)   0.610     1.09 (0.55--2.2)    0.798

  IIA                     2.36 (1.15--4.85)   0.020              2.05 (1.08--3.91)   0.029             1.42 (0.77--2.64)   0.261     1.75 (0.9--3.43)    0.102

  IIB                     1.92(0.69--5.31)    0.212              1.67(0.72--3.87)    0.228             2.91(1.67--5.05)    \<0.001   3.92(2.12--7.26)    \<0.001

  IIIA                    5.63(2.64--12.02)   \<0.001            4.52(2.36--8.66)    \<0.001           4.19(2.35--7.45)    \<0.001   6.3(3.29--12.06)    \<0.001

  **Vascular invasion**                                                                                                                                  

  No                                                                                                                                                     

  Yes                     2.36(1.31--4.26)    0.004              2.01(1.23--3.31)    0.006             1.47(0.96--2.27)    0.078     1.53(0.93--2.53)    0.097
  ----------------------- ------------------- ------------------ ------------------- ----------------- ------------------- --------- ------------------- ---------

*Abbreviations*: FAP-1, Fibroblast activating protein 1; NSCLC, non small-cell lung cancer; CD8, cluster of differentiation 8; ECOG, Eastern Cooperative Oncology Group.

Discussion {#sec015}
==========

A major finding from this *in situ* study is that the levels of CAFs did not correlate markedly with the infiltration of major leukocyte subsets into NSCLC tumor tissue ([Fig 2B](#pone.0192157.g002){ref-type="fig"}), indicating that CAFs may not play a dominant role in the regulation of leukocyte recruitment/infiltration in these tumors. Interestingly, survival analyses show that high levels of CAF^FAP^ in CD3/CD8 infiltrated tumors correlate with increased patient survival. This finding may suggest that CAF^FAP^ positively influence the effector function of cytotoxic tumor infiltrating lymphocytes.

The utilization of a TMA approach, rather than whole tissue slides, may partly explain the lack of correlations between CAFs and leukocyte subsets. However, the potential negative effect of using TMA in this context should be negated by the sheer number of patients included in the study and the inclusion of duplicate cores from each patient leading to increased representativeness. In addition, the presence of phenotypically different subsets of CAFs may differ between tumor regions due to heterogeneity. Neither TMA, nor whole slide studies are able to fully address this issue. Double, triple or quadruple IHC staining would ensure intra-patient sample homogeneity and would allow co-localization of CAF markers on the same cells. However, the issue of inter-patient sample heterogeneity, due to structurally and functionally different tumor areas being investigated in each patient, will remain a problem. Moreover, the spatial organization of the immune cell infiltrate, which discriminates between peritumoral and intratumoral areas is not addressed in TMA-based analyses. This is a relevant point that should be considered at the time of interpreting the results from this study. In this work, we lack information on peritumoral areas or the invasive front of tumors. However, we have considered the distinction between stromal and intratumoral areas.

Tumor fibroblasts, or CAFs, refers to a heterogeneous population of mesenchymal cells occurring during tumor development. Each subclass express different sets of cellular markers, and probably exert different regulatory functions in the context of cancer \[[@pone.0192157.ref001]\]. Despite the well-defined set of markers to identify mesenchymal cells, it is not possible to differentiate CAF subtypes based merely on the overlapping or non-overlapping expression of these markers \[[@pone.0192157.ref035]\]. Hence, we selected a panel of frequently used markers of fibroblast activation, and analyzed them separately. Initially, we checked for correlations between CAF-markers to study CAF diversity in NSCLC ([Table 1](#pone.0192157.t001){ref-type="table"}, [Fig 2A](#pone.0192157.g002){ref-type="fig"}). Notably, vimentin, PDGFRα, PDGFRβ and FAP-1 showed modest correlation and did not correlate with αSMA and MT (collagen). Hierarchical clustering indicate the existence of different CAF subsets. Intriguingly the expression patterns of FAP-1 and αSMA, two of the most frequently used markers of CAF activation, showed distinct expression patterns when the staining was conducted in the same tumor specimen ([Fig 3](#pone.0192157.g003){ref-type="fig"}), clearly demonstrating the existence of phenotypically different CAF subsets in NSCLC tumors. Additionally, FAP-1 was not exclusively expressed by CAFs in tumors; since positive expression was also found in macrophage like cells, as previously observed for other tumor types \[[@pone.0192157.ref036]\]. However, our scoring was restricted to FAP-1 expression in fibroblast-like cells. In addition, PDGFRα expression by neoplastic epithelial cells was observed in about 15% of the cases.

In our cohort of unselected stage I-IIIA NSCLC patients, we have previously studied more than 100 prognostic markers related to *in situ* immunology \[[@pone.0192157.ref037]--[@pone.0192157.ref039]\], angiogenesis \[[@pone.0192157.ref030], [@pone.0192157.ref034]\], and epithelial-mesenchymal transition \[[@pone.0192157.ref010]\]. In this study, we have capitalized on these previous analyses and checked for correlations between CAF-markers and a panel of different leukocyte markers in the same patient cohort. Overall, the different CAF-markers do not show strong correlations with any of the selected myeloid or lymphoid immune markers, which included CD3, CD4, CD8 (T-lymphocytes), CD20 (B-lymphocytes), CD68 (TAMs), CD1a (dendritic cells DCs), CD56 (NK cells), FoxP3 (Treg) and CD45RO (T-memory cells). Moderate positive correlations were observed between CAF^FAP^ and CAF^PDGFRβ^ with FoxP3, and between CAF^PDGFRα^ and CD3 or CD20 ([Fig 2B](#pone.0192157.g002){ref-type="fig"}). The positive associations of CAF subsets with T regulatory cells highlight a potential CAF-mediated immuno-regulatory mechanism connected to the chemotaxis of immuno-suppressive cells.

The interplay between CAFs and immune cells has been recognized as a major contributor in cancer development as summarized in recent reviews \[[@pone.0192157.ref023], [@pone.0192157.ref040]\]. CAFs may influence trafficking and function of effector immune cells indirectly by modulating ECM deposition and stiffness, via the synthesis of ECM components such as collagens, fibronectin and laminin, or by the release of matrix remodeling agents including MMPs, cathepsins or proteases of the uPA system \[[@pone.0192157.ref041], [@pone.0192157.ref042]\]. In our study we have identified correlations between CAF^αSMA^ and collagen deposition in tumors (by MT), indicating that CAFs expressing αSMA (myofibroblasts) may be the main cells responsible for ECM formation in NSCLC tumors. However, no clear correlations were found between MT or CAF^αSMA^ patterns and the infiltration of immune cells.

According to numerous pre-clinical studies, the pleiotropic immune-modulatory functions of CAFs are orchestrated primarily through the production of a plethora of cytokines, chemokines and small molecules functioning in a paracrine fashion \[[@pone.0192157.ref043], [@pone.0192157.ref044]\]. Moreover, CAFs have been shown to regulate recruitment and polarization of innate immune cells such as macrophages and neutrophils via secretion of factors like CCL5, MCP-1/CCL2, IL-6, IL-8, CXCL10 and CXCL14 \[[@pone.0192157.ref018], [@pone.0192157.ref045]\]. In the presented study, results do not reveal clear associations between CAFs and intratumoral levels of either TAMs (CD68) or DCs (CD1a). Whether CAFs influence the functional polarization of TAMs or DCs *in vivo*, remains to be elucidated. In future studies, the phenotypic stage of these cells should be established by the use of differentiation markers such as CD206 (M2 macrophages), iNOS (M1 macrophages) or CD303 (plasmacytoid DC).

Furthermore, CAFs regulate recruitment and activation of adaptive immune cells via the release of peptide signals such as transforming growth factor β1 (TGFβ1), tumor necrosis factor-α (TNFα), stromal-derived factor 1 (SDF-1), or thymic stromal lymphopoietin (TSLP) \[[@pone.0192157.ref046]--[@pone.0192157.ref049]\]. In our NSCLC patient cohort, we have investigated associations between CAF subtypes and lymphoid cells including T-cells (CD3^+^), CD4^+^ T-helper cells, CD8^+^ cytotoxic lymphocytes, memory T-cells (CD45RO), T-regulatory cells (FoxP3^+^), B-lymphocytes (CD20^+^) and NK cells (CD56^+^). No relevant correlations were observed between CAFs and adaptive immune cells. However, with the intention of checking CAF influence on T-cell effector functions, survival rates in patients with high or low infiltration rates of CD3^+^ and CD8^+^ T-cells were compared. Intriguingly, in the subgroup of patients with tumors highly infiltrated by lymphocytes, the presence of CAF^FAP^ was a positive prognostic factor. This observation suggests that CAF^FAP^ may---directly or indirectly---exert positive immuno-adjuvant effects. On the contrary, increased CAF^PDGFRβ^ levels were associated with adverse prognosis in patients with tumors poorly infiltrated by T-lymphocytes ([S3 Fig](#pone.0192157.s003){ref-type="supplementary-material"}). This latter finding indicate that CAF^PDGFRβ^ exerts no influence on the tumor immune response. Combined, the results of CAF^FAP^ and CAF^PDGFRβ^ support the theory of functionally different and/or context-dependent CAF subclasses exerting divergent immune-modulatory effects in NSCLC, despite the assumption that both FAP-1 and PDGFRβ are considered specific markers for activated CAFs. FAP-1, also known as seprase, is a ubiquitously expressed membrane bound serine protease that has both dipeptidyl peptidase and endopeptidase activities, cleaving substrates at post-proline bonds. FAP-1 is essentially undetectable in non-disease tissues, but greatly enhanced at sites of tissue remodeling, including fibrotic tissue reactions, chronically inflamed tissues, epithelial cancers and embryonic tissues. The role of this protease as regulator of the immune system is uncertain. However, selective depletion of FAP-1-positive fibroblasts in murine models of pancreatic cancer has been shown to enhance anti-tumor immunity and delay tumor growth \[[@pone.0192157.ref050]\].

Generally, CAFs have been considered to promote an immunosuppressive microenvironment, but this may be context dependent rather than a specific feature of CAFs. Most of the accumulated evidence in this regard are limited to *in vitro* experiments, or animal experiments with admixed fibroblasts previously expanded *in vitro* which do not recapitulate the CAF heterogeneity observed *in vivo*. Only a handful of studies, with diverging outcomes, have investigated immunoregulatory effects of CAFs *in vivo* by selective depletion of CAF subsets. In genetically engineered murine models, selective depletion of CAF^FAP^ showed antitumor effects via intratumoral recruitment of CD8+ T cells \[[@pone.0192157.ref050]\]. On the contrary, specific depletion of CAF^αSMA^ led to invasive tumors associated with an immunosuppressive adaptive response \[[@pone.0192157.ref025]\]. Besides, clinical studies in pancreas, breast and lung cancer that correlate ECM or CAF-markers with disease outcomes have shown that patients with high desmoplasia or CAF infiltration can have improved prognosis and overall survival \[[@pone.0192157.ref051]\]. The presented explorative study propose a beneficial prognostic role played by CAF^FAP^ in immune infiltrated tumors, and underscores the need of caution in targeting CAF^FAP^ as a therapeutic strategy in lung cancer. However, additional functional studies should be considered to conclusively demonstrate causal effects of CAF subtypes on the anti-tumor immune responses.
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